Artificial Bone Graft Substitutes for Curettage of Benign and Low-Grade Malignant Bone Tumors: Clinical and Radiological Experience with Cerasorb
-
Published:2023-06-22
Issue:9
Volume:57
Page:1409-1414
-
ISSN:0019-5413
-
Container-title:Indian Journal of Orthopaedics
-
language:en
-
Short-container-title:JOIO
Author:
Wittig Ulrike SusanneORCID, Friesenbichler Jörg, Liegl-Atzwanger Bernadette, Igrec Jasminka, Andreou Dimosthenis, Leithner Andreas, Scheipl Susanne
Abstract
Abstract
Background
Artificial bone graft substitutes (ABGS) for curettage of bone tumors are becoming increasingly popular. The aim of this retrospective analysis was to determine the efficacy of the ABGS Cerasorb (Curasan-AG, Kleinostheim, Germany), a beta-tricalcium phosphate (beta-TCP), concerning resorption profile, bone healing, and remodeling after surgery and to evaluate potential complications.
Methods
Forty-three patients suffering from benign and low-grade malignant bone tumors were treated with curettage and refilling of the bony cavity using the ABGS Cerasorb between 2018 and 2021 and included in the final analysis. Clinical follow-up exams with X-rays in two planes were performed 6 weeks, 3 months, 6 months, and 1 year after surgery.
Results
After a mean follow-up period of 14.6 months, radiological consolidation following curettage was observed in all patients. Total resorption was observed in 16.3% of patients; in the other 83.7%, resorption was partial. In four patients, of whom two had a tumor in the distal femur and two in the humeral diaphysis, fractures occurred within 6 weeks after primary surgery.
Conclusion
In conclusion, the beta-TCP Cerasorb seems to be a reliable bone graft substitute with low complication rates and is a suitable alternative to autologous bone grafts or allografts. Nonetheless, it shows a tendency of delayed resorption.
Level of Evidence
III; retrospective cohort study.
Funder
Medical University of Graz
Publisher
Springer Science and Business Media LLC
Subject
Orthopedics and Sports Medicine
Reference26 articles.
1. Friesenbichler, J., Maurer-Ertl, W., Sadoghi, P., Pirker-Fruehauf, U., Bodo, K., & Leithner, A. (2014). Adverse reactions of artificial bone graft substitutes: Lessons learned from using tricalcium phosphate geneX(R). Clinical Orthopaedics and Related Research, 472(3), 976–982. 2. Van Hoff, C., Samora, J. B., Griesser, M. J., Crist, M. K., Scharschmidt, T. J., & Mayerson, J. L. (2012). Effectiveness of ultraporous beta-tricalcium phosphate (vitoss) as bone graft substitute for cavitary defects in benign and low-grade malignant bone tumors. American Journal of Orthopedics, 41(1), 20–23. 3. Kurz, L. T., Garfin, S. R., & Booth, R. E., Jr. (1989). Harvesting autogenous iliac bone grafts. A review of complications and techniques. Spine, 14(12), 1324–1331. 4. Tomford, W. W., Starkweather, R. J., & Goldman, M. H. (1981). A study of the clinical incidence of infection in the use of banked allograft bone. Journal of Bone and Joint Surgery. American Volume, 63(2), 244–248. 5. Sutherland, A. G., Raafat, A., Yates, P., & Hutchison, J. D. (1997). Infection associated with the use of allograft bone from the north east Scotland Bone Bank. Journal of Hospital Infection, 35(3), 215–222.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|